Angel Cat Sugar products arriving at retail
HOLLYWOOD, Calif. A new character brand, Angel Cat Sugar, is making its retail debut, thanks to a flurry of new licensing deals.
Dan-Dee International is slated to carry the Angel Cat Sugar seasonal plush at CVS/pharmacy, Walgreens and Walmart, said the brand’s property manager, Paramount Licensing. In the United States, licensees now include:
- Boston America – lip balm, lip gloss and cosmetics kits;
- Brown Trout – wall calendars;
- Dan-Dee Int’l – plush;
- Kellytoy – amusement and crane plush and novelty sporting goods;
- MediBadge – stickers, temporary tattoos;
- Pioneer Balloon Co. – balloons, play balls;
- Scholastic – story books and activity books; and
- University Games – board games and puzzles.
‘Battle of the bulge’ solved with Perfect Fit Button
FAIRFIELD, N.J. Need a quick fix for pants that just don’t fit right? Look no further than the Perfect Fit Button, an innovative new product that helps prolong the comfortable fit of pants, jeans or skirts by creating an easy way to adjust the waistband.
Made by TeleBrands, the company behind such products as storage solution Shoes Under and PedEgg, the Perfect Fit Button is the newest way to get pants and skirts to fit without having to spend extra money. It retails for $9.99 for a set of eight.
Patient enrollment complete for lung cancer treatment trial
SOUTH SAN FRANCISCO, Calif. Drug maker OXiGENE has finished enrolling patients for a mid-stage clinical trial of a lung cancer treatment, the company said Wednesday.
OXiGENE announced that it had enrolled 60 patients in “FALCON,” a phase 2 trial of the drug Zybrestat, a treatment for non-small cell lung cancer. The trial comprises two arms, a study arm with patients taking Zybrestat with Genentech’s Avastin (bevacizumab) and chemotherapy, and a control arm with patients taking Avastin and chemotherapy alone. OXiGENE said some preliminary results from the trial presented at the recent meeting of the American Society of Clinical Oncology have indicated that the drug is safe and effective.
“We look forward to presenting a more complete analysis of the FALCON trial later in 2010 at a scientific meeting,” OXiGENE CEO Peter Langecker said. “If the encouraging positive trends in terms of progression-free survival and overall survival that we presented at ASCO are maintained, they will underscore Zybrestat’s utility in non-small cell lung cancer and potentially pave the way toward embarking upon a registration pathway.”